ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) saw a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 8,390,000 shares, a growth of 17.0% from the November 30th total of 7,170,000 shares. Currently, 24.4% of the shares of the stock are short sold. Based on an average trading volume of 937,300 shares, the short-interest ratio is presently 9.0 days.

Insider Activity

In other news, Director Rekha Hemrajani acquired 30,000 shares of the stock in a transaction dated Monday, December 2nd. The stock was bought at an average price of $1.55 per share, with a total value of $46,500.00. Following the completion of the purchase, the director now directly owns 33,000 shares of the company's stock, valued at $51,150. This represents a 1,000.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 33.40% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ALX Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of ALXO. Point72 Asset Management L.P. bought a new position in shares of ALX Oncology in the 2nd quarter worth about $1,834,000. GSA Capital Partners LLP acquired a new stake in ALX Oncology during the third quarter worth approximately $88,000. Marshall Wace LLP increased its holdings in ALX Oncology by 423.0% in the second quarter. Marshall Wace LLP now owns 635,679 shares of the company's stock worth $3,833,000 after purchasing an additional 514,133 shares in the last quarter. SG Americas Securities LLC lifted its stake in ALX Oncology by 33.6% in the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company's stock valued at $50,000 after buying an additional 6,888 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in ALX Oncology by 394.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company's stock valued at $39,000 after buying an additional 5,200 shares during the period. Institutional investors and hedge funds own 97.97% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of ALX Oncology in a research report on Wednesday, December 18th. Jefferies Financial Group downgraded ALX Oncology from a "buy" rating to a "hold" rating and decreased their price objective for the company from $12.00 to $2.00 in a report on Thursday, December 19th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $25.00 target price on shares of ALX Oncology in a report on Wednesday, December 18th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $8.50.

ALX Oncology Trading Down 4.1 %

Shares of NASDAQ:ALXO traded down $0.07 during trading on Friday, reaching $1.62. The stock had a trading volume of 470,455 shares, compared to its average volume of 830,145. ALX Oncology has a 52 week low of $1.19 and a 52 week high of $17.83. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. The firm's fifty day moving average is $1.52 and its 200 day moving average is $3.00. The stock has a market cap of $85.44 million, a price-to-earnings ratio of -0.54 and a beta of 1.04.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.